# 1. Financial Performance ## A. Key Figures * **Revenue:** **₹444 Cr** Q2 (+5.7% YoY, +10.1% QoQ) · **₹847 Cr** H1 (+5.3% YoY) * **Gross Profit & Margin:** **₹308 Cr** Q2 (69% margin, +99 bps YoY) · **₹584 Cr** H1 (69% margin, +137 bps YoY) * **EBITDA & Margin:** **₹119 Cr** Q2 (27% margin) · **₹226 Cr** H1 (27% margin, -400 bps YoY) * **PAT & Margin:** **₹92 Cr** Q2 (+5% YoY, 19.2% margin) · **₹185 Cr** H1 (+5% YoY, 20% margin) * **Net Cash Position:** **₹600 Cr** pre-acquisition · **₹800 Cr** post-Citieffe acquisition ## B. Revenue Growth * **Resilient Top-Line Performance:** Revenue growth remained positive despite macro headwinds, with **strong double-digit gross margin expansion** driving profitability. ## C. Profit Margins * **Margin Re-Rating Underway:** Gross margins expanded significantly YoY, reflecting operational leverage and cost optimization, even as EBITDA margins declined due to **one-time acquisition costs**. * **Guidance Reaffirmed:** Management remains confident in achieving the **25%-27% full-year EBITDA margin target**, supported by ongoing margin improvement initiatives. ## D. Balance Sheet * **Robust Liquidity Profile:** Strong net cash position provides flexibility for **both organic investments and strategic inorganic opportunities**, including recent PendraCare and Citieffe acquisitions. ## E. Cash Flow * **Working Capital Efficiency:** Cash conversion cycle remains within a manageable range of **50–120 days**, with debtor days at **~80 days**, indicating stable collections and operational discipline. --- # 2. Segment & Business Mix ## A. Key Figures * Domestic Revenue Growth: **17–18%** YoY in Q2 & H1 FY'26 (now **32%** of consolidated revenue) * International Revenue: **₹300 Cr** in Q2 FY'26 (+9.1% QoQ, +5% seq. from Q1) · **9.6% YoY decline** due to Europe headwinds * **ROW Revenue Growth:** **~13% YoY** sequentially, driven by direct sales and outreach * Renal Revenue: **₹44 Cr** in Q2 FY'25 (+18.1% YoY) · **₹88 Cr** in H1 FY'25 (~30% YoY) · FY target: **>₹200 Cr** (down from ₹220–250 Cr) * **Dialysis Machines Sold:** **>200** in H1 FY'26 · **~300** expected in H2 * **Cardiology Device Deployments:** **>4,000 stents** in H1 FY'26 ## B. Domestic vs International * **Domestic Momentum:** Strong double-digit growth in domestic revenue, now representing a larger share of the consolidated base, driven by strategic execution and market demand. * **International Recovery Signs:** Sequential improvement in international revenue after weak Q1, with Europe showing early signs of stabilization and improving customer sentiment supporting H2 rebound expectations. * **Geographic Expansion Plans:** PACE academies set for rollout across India and overseas, signaling long-term capacity and brand-building investments. * **US Market Progress:** Early but meaningful traction with one major customer onboarded and initial product supply underway, despite challenging conditions. * **Global Market Opportunity:** Polymed captures only **2–3%** of the **₹65,000 Cr** global medtech market, highlighting vast untapped potential, especially in Vascular Access and Infusion, which drive **68%** of total revenue. ## C. Private vs Government * **Strategic Shift to Private Sector:** Deliberate de-emphasis on low-margin government tenders (L1-driven, no quality premium) has reduced govt. share to **10%** of domestic business, favoring higher-margin private channel expansion. * **Hospital Wallet Share Upside:** Current penetration estimated at **5–7%** per hospital, with potential to double within existing accounts, despite market fragmentation and data gaps. * **Medical Device Cost Insight:** Devices represent **~10%** of total treatment costs in Indian hospitals—lower than prior estimates—indicating room for value-based pricing and adoption growth. ## D. Renal Business * **Renal Growth Moderated by GST Impact:** Full-year revenue guidance revised down to **>₹200 Cr** from **₹220–250 Cr** due to inventory alignment post-GST changes, though H1 performance showed strong ~30% YoY growth. * **Dialysis Machine Rollout Accelerating:** Over 200 machines deployed in H1 with ~300 more expected in H2, supported by unmet demand, government backing, and expanding service infrastructure. * **Cardiac & Critical Care as Growth Engines:** Both segments gaining traction, with **>4,000 stents** deployed in H1 and **20+ new products** launched in Critical Care, now present in **500 hospitals**. * **Import Substitution Advantage:** High import dependency (**80–90%**) in Cardiology and Critical Care creates strong tailwinds for Polymed’s locally manufactured offerings, particularly in Cardiac where import substitution is accelerating. * **Competitive Positioning:** Critical Care offers superior margins and fewer global players (**4–5**) versus crowded Cardiology space (**~20**), giving Polymed a structural edge in scaling the former. * **Tier-1 City Entry Pending:** Cardiology currently focused on Tier-2/3 cities; entry into Tier-1 delayed by clinical study requirements, though pipeline includes **drug-eluting balloons** and **PTCA catheters** for near-term launch. --- # 3. Product & Regulatory Progress ## A. Key Figures * **Products Offered:** **250** out of ~50,000 in med-tech industry * **Pipeline Volume:** **60–80** new products in development (2026–2029 launches) * **CE-Certified Products:** **75** currently · **20** new CE marks expected by **2026** * **Clinical Trial Size:** **2,000-patient** study for RisoR stent (vs. peers: 500–1,000) ## B. New Product Launches * **Strategic Platform Rollout:** Launch of PACE and expanded SARATHI AI program strengthens KOL engagement and frontline capability, reinforcing scientific leadership positioning. * **High-Margin Growth Vector:** New offerings in **Cardiology** and **Critical Care**—plus upcoming **Orthopedics** expansion—target higher-margin segments and underpenetrated markets. * **Significant White Space:** Absence in **Urology, Gastroenterology, Neurology**, and other key specialties highlights substantial long-term addressable market opportunity. * **European Portfolio Build:** 20 upcoming CE-marked products represent adjacent extensions in **Oncology, Neonatal**, and **Pain Management**, broadening European footprint. ## C. CE & FDA Clearances * **US Market Momentum:** FDA clearance secured for **two new IV catheters**, with commercial supply starting in Q4 and a key customer launch planned in Q3. * **Regulatory Discipline:** Full re-certification under EU MDR completed for legacy portfolio, de-risking European revenue continuity. * **Pipeline of Approvals:** 20 additional products submitted for regulatory review with clearances anticipated from **early 2026**, supporting near-term international growth. ## D. Clinical Trials * **Differentiated Trial Scale:** RisoR stent under evaluation in the **largest ongoing stent trial** (2,000 patients), designed to generate superior clinical evidence versus competitors. * **Evidence-Driven Adoption:** Management emphasizes robust clinical data as central to clinician uptake, with trial follow-up extending up to **one year post-implant**. --- # 4. Capacity & Manufacturing ## A. Key Figures * **CAPEX (H1 FY'26):** **₹150 Cr** (incurred) · **₹250 Cr** planned for full-year FY'26 * **CAPEX Guidance:** **₹250 Cr** allocated for FY'26 · **₹500 Cr** raised via QIP (partial allocation to organic CAPEX) * **Future CAPEX:** **Similar level to FY'26** expected in FY'27 ## B. Plant Expansion * **Progress on Key Sites:** Phase-I completed at both **Faridabad** and **Haridwar** plants; Phase-II on track for completion by end-2026. * **Faridabad Facility Advances:** Gama sterilization unit operational in part, with full licenses secured from CDSCO and government. * **Revenue Timeline:** Partial revenue contribution expected from Faridabad and Haridwar in FY'27, with full ramp-up anticipated in FY'28. ## C. CAPEX Plan * **Spending Execution:** H1 CAPEX of ₹150 Cr aligns with plan; remaining ₹100 Cr to be deployed in H2, supporting new facilities in Mitral and Haridwar. * **Funding Strength:** QIP raise of ₹500 Cr provides financial flexibility, with dedicated allocation for organic expansion. * **Forward-Looking Investment:** CAPEX intensity to remain stable in FY'27 as construction progresses across multiple sites. ## D. Land Acquisition * **Strategic Shift:** Dropped Jaipur facility plans; acquired **7 acres in YEIDA**, positioned **3 km from Jewar airport**, for new medical device park. --- # 5. M&A & Strategic Expansion ## A. Key Figures * **Acquisition Revenue Add:** **₹280 Cr** annualized (+~10% of H2 guidance) ## B. Recent Acquisitions * **Strategic Market Entry:** Completed acquisition of **Citieffe Group (Italy)**, marking entry into the **Ortho segment** and expanding total addressable market by **~$70 billion**. * **European Cardiology Expansion:** Acquired **PendraCare Group (Netherlands)**, strengthening interventional cardiology offerings and establishing **manufacturing and distribution footprint in Europe**. * **Technology-Driven Growth:** Two acquisitions completed in the quarter focused on **Critical Care, Cardiology, and adjacent high-potential segments**, with future deals expected to deepen vertical integration. * **Land-Driven Acquisition:** Acquired **Himalayan Mineral Waters via NCLT** solely for **20,000 sqm of adjacent land in Haridwar**, supporting long-term domestic capacity expansion. * **Global Clinical Momentum:** **Stent clinical trials initiated in India and Europe**, bolstered by PendraCare’s regulatory and commercial infrastructure. ## C. Integration Progress * **Synergy Confidence:** Integration of **Citieffe and PendraCare** underway, with management confident in realizing **significant operational and commercial synergies**. * **Proven Turnaround Track Record:** Earlier acquisition **Plan1 Health** transformed from **negative EBITDA** to **16%-17% EBITDA margin**, showcasing successful integration and supply chain optimization. * **Phased Integration Timeline:** Full integration expected over **a couple of quarters**, with Citieffe now under full control and PendraCare recently closed; no near-term financial guidance provided. * **Margin Outlook:** Acquisition-related revenue may be **margin dilutive in the near term**, though long-term improvement is anticipated. ## D. Synergy Potential * **Margin Expansion Pathway:** Acquired entities historically generated **~15% EBITDA margins**, with potential to exceed **20%** through **India-sourced manufacturing** and scale via **Polymed’s global distribution network**. * **Geographic Diversification:** Targeted investments in **underpenetrated markets** to counter European softness, aiming for **sequential quarterly improvement in H2**. --- # 6. Risks & Regulatory Hurdles ## A. US Regulatory Delays * **Regulatory Setback:** US market entry delayed due to FDA policy change rejecting Indian lab results, nullifying prior work and requiring full retesting in the US. * **Path to Resolution:** New US-based testing underway for 3–4 months; results expected April–May, with new FDA submissions targeting **mid-next-year market entry**. * **Sector-Wide Impact:** Regulatory shift affects all Indian medtech exporters, linked to broader US administration policy changes. ## B. Tariff & Market Access * **Persistent Tariff Disadvantage:** India faces **50% tariffs** on medical devices versus lower rates in competing ASEAN nations, reducing attractiveness for US buyers. * **Unchanged US Pipeline:** Despite headwinds, **$15–$20 million product pipeline** for the US remains intact, reflecting long-term strategic commitment. ## C. European Competition * **Easing Logistics Pressure:** Suez Canal transit times improved from **5 months to ~1 month**, aiding inventory management and mitigating Chinese product dumping. * **Competitive Differentiation:** Intensified rivalry from Chinese exporters persists; company counters with **innovation and regulatory preparedness**. * **Domestic Rivalry:** Indian cardiology peers hold advantage with **longer market presence** and established **international clinical trial data**. --- # 7. Guidance & Outlook ## A. Key Figures * **Domestic Revenue Growth Guidance:** **28%-30%** for FY '26 * **International Revenue Growth Guidance:** **~10%** for FY '26 * **H2 FY'26 Revenue Guidance:** **₹1,080–1,090 Cr** (vs. H1 ~₹850 Cr) * **Full-Year Revenue Growth Guidance (FY '26):** **15%-16%** (revised from 20%) * **Operating EBITDA Margin Guidance:** **25%-27%** for FY '26 (H1 >26%) ## B. Revenue Forecast * **Downgraded Top-Line Outlook:** Full-year growth guidance trimmed to 15%-16% due to **geopolitical and macro headwinds** in exports, despite strong domestic momentum. * **Robust Domestic Resilience:** 28%-30% domestic growth maintained as a target, underscoring confidence in local demand despite a **14% decline in government business**. * **H2 Acceleration Expected:** Second-half revenue set for **>25% sequential growth**, driven by **90% organic expansion** and 10% from recent acquisitions. * **India’s Oncology Push a Tailwind:** Government’s plan to establish **200 new Specialty Oncology Centers** this year (700 over 3 years) aligns with Critical Care’s strategic focus. ## C. Margin Target * **Margins on Track:** Operating EBITDA margin guidance of 25%-27% reaffirmed, with H1 performance already **exceeding 26%**, reflecting strong cost discipline. ## D. Growth Trajectory * **Innovation-Led Recovery:** **Pipeline of ~20 new products** (vs. 75 CE-certified) expected to restore European sales and shift growth trajectory by next year. * **Long-Term Runway Secured:** Management sees a **5-10 year innovation cycle** ahead, supported by R&D investment and a new manufacturing plant for global scale. * **Cautious International Optimism:** Green shoots in international markets emerging; targeting return to prior-year European sales levels by early next year. * **Strategic Reinvestment:** Focus on sustainability, R&D, and capacity expansion reinforces long-term resilience despite conservative near-term guidance.